Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellestia Biotech AG
Celgene
Incyte Corporation
INSYS Therapeutics Inc